Taiwan local active trials in Immuno-Oncology
Committed to Immuno-Oncology research
The Bristol-Myers Squibb I-O portfolio consists of novel agents in development that are designed to target various immune mechanisms that may enhance antitumor immune response. We are investigating the potential of I-O in a wide range of cancers, as well as combinations of I-O agents with the hope of optimizing clinical outcomes.